- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07928167
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Metastatic clear cell renal cell carcinoma (mRCC) is sensitive to combination of lenvatinib and pembrolizumab. The CLEAR study showed positive results in patients with low tumor burden. However, around 20% of patients do not respond and have stable disease. In the VOLGA study, we demonstrated better outcomes in patients with irradiation of even a single lesion during targeted therapy. Thus, investigators hypothesize that stereotactic radiotherapy (SBRT) to multiple lesions in patients undergoing ongoing therapy with pembrolizumab and lenvatinib will increase the objective response rate, which may correlate with improved overall survival.
LASER is a randomized multicenter phase 2 study. Initially, all patients with histologically confirmed mRCC, the median sum of the diameters of target lesions ≥ 7 cm, ECOG 0-2, and the absence of prior systemic therapy for metastatic disease will receive a 12-week induction with lenvatinib and pembrolizumab, followed by radiological assessment according to RECIST 1.1 and allocation by outcome (response, stable disease, or disease progression). Patients with stable disease (SD) will be randomized in a 1:1 ratio into two groups: 1) lenvatinib + pembrolizumab + SBRT (N=27) or 2) lenvatinib + pembrolizumab alone (N=27). In the SBRT group, the choice of target for irradiation - up to 3 (three) lesions - is determined by a multidisciplinary team. The primary endpoint is the objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease (assessed every 12 weeks according to RECIST 1.1). The statistical hypothesis is based on an expected ORR of 15% in the control group versus 50% in the SBRT group. A two-sided α of 0.05 and a power of 80% require 27 patients in each group (54 randomized). The total enrollment will be 150 patients.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ilya Tsimafeyeu
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
Lieux d'étude
-
-
-
Kazan', Russie, 420000
- Recrutement
- Republican Dispensary of Tatarstan
-
Contact:
- Milyausha Mukhitova
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Russie, 115478
- Recrutement
- N.N. Blokhin National Medical Research Center of Oncology
-
Contact:
- Petr Bulychkin
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Russie, 125630
- Recrutement
- STOONCO clinic
-
Contact:
- Valentina Leonenko
- Numéro de téléphone: +7 (915) 809-03-03
- E-mail: bucare@bucare.org
-
Orenburg, Russie, 460000
- Recrutement
- Orenburg Regional Cancer Center
-
Contact:
- Makhabbat Murzalina
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
-
Saint Petersburg, Russie, 194291
- Recrutement
- SBHI Leningrad Regional Clinical Hospital
-
Contact:
- Andrey Lebedinets
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
-
Tyumen, Russie, 625000
- Recrutement
- Cancer Center "Medical City"
-
Contact:
- Vera Peryshkina
- Numéro de téléphone: +74999054690
- E-mail: sten_to@mail.ru
-
Ufa, Russie, 450000
- Recrutement
- Republican Clinical Oncology Dispensary
-
Contact:
- Alexander Sultanbaev
- Numéro de téléphone: +7 (347) 216-3671
- E-mail: ufa.rkod@doctorrb.ru
-
Ulyanovsk, Russie, 432000
- Recrutement
- "ErSpace" Radiation Therapy Center
-
Contact:
- Natalia Dengina
- Numéro de téléphone: +78422737472
- E-mail: info@rspei.ru
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed clear-cell renal cell carcinoma.
- Presence of measurable lesions per RECIST 1.1.
- Sum of diameters of target lesions ≤ 7 cm.
- ECOG 0-2.
- No prior systemic therapy for metastatic disease.
Exclusion Criteria:
- Uncontrolled comorbidities that preclude the use of TKI/IO or SBRT.
- Prior SBRT to the lesions planned for irradiation, rendering re-irradiation unsafe.
- Active autoimmune diseases requiring systemic immunosuppressants.
- Symptomatic CNS metastases (patients with asymptomatic metastases may be included).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Lenvatinib + Pembrolizumab + SBRT
|
20 mg orally once daily. 200 mg intravenously every 3 weeks The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion. |
|
Comparateur actif: Lenvatinib + Pembrolizumab
|
20 mg orally once daily. 200 mg intravenously every 3 weeks |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Response of unirradiated lesions according to RECIST v1.1
Délai: Percentage of patients with response at week 12
|
Objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease |
Percentage of patients with response at week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Median progression-free survival
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
|
Median overall survival
Délai: From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
|
Median duration of response
Délai: From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
|
Rate of local control of irradiated lesions
Délai: Percentage of stable irradiated lesions at week 12
|
Percentage of stable irradiated lesions at week 12
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Délai: Rate of treatment-related adverse events at week 24
|
Rate of treatment-related adverse events at week 24
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Ilya Tsimafeyeu et al. A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).. J Clin Oncol 44, TPS583-TPS583(2026). DOI:10.1200/JCO.2026.44.7_suppl.TPS583
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Processus néoplasiques
- Tumeurs urologiques
- Carcinome
- Tumeurs rénales
- Conditions pathologiques, signes et symptômes
- Métastase néoplasmique
- Carcinome à cellules rénales
- Techniques d'investigation
- Thérapeutique
- Procédures chirurgicales, opératoires
- Radiothérapie
- Techniques stéréotaxiques
- Procédures neurochirurgicales
- pembrolizumab
- Radiochirurgie
- lenvatinib
Autres numéros d'identification d'étude
- LASER
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
In accordance with local legislation
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .